Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Master's Award: Canada Graduate Scholarships

University of Guelph

$27,000.00

Exploring the Role of a Novel Compound in Remodeling the Ovarian Tumor Microenvironment to Optimize Therapeutic Response to Metronomic Chemotherapy While Preserving Ovarian Function and Fertility

FY 2024-25

Summary
Ovarian cancer is the most lethal gynecological cancer, affecting 1 in 87 women worldwide. It is often diagnosed in advanced stages (III-IV) making treatment less effective. Although most cases occur in women over the age of 60, 12.1% affect those under 44, whom are still of reproductive age. Current treatments cause significant fertility damage, such as depleting the ovarian reserve and leading to infertility or premature menopause in survivors. There is a strong need for fertility preserving strategies to reduce the physical and emotion burden on women. Currently, oocyte and embryo cryopreservation exist; however, it often delays treatment that may worsen cancer outcomes. Additionally, fertility preservation itself may damage ovarian and reproductive tissue preventing successful future pregnancies. There is also a debatable concern that fertility drugs could increase ovarian cancer risk. This study combines low-dose metronomic chemotherapy with Fc3TSR, a peptide that normalizes tumor vessels to improve drug delivery. We hypothesize that Fc3TSR combined with low-dose metronomic chemotherapy will maintain ovarian functionality better than the current high-dose chemotherapy procedures. Using a mouse model, we will analyze the effects of fertility after treatment groups, including, reproductive hormone levels, ovary follicular development, oocyte fertilization capability and litter numbers. Along with analyzing fertility parameters, we will be examining the treatment effects on cancer elimination. We expect this approach to improve fertility preservation while maintaining effective cancer treatment; offering a potential treatment option for women who wish to maintain fertility.
Program
Master's Award: Canada Graduate Scholarships
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
530141
Name
Lockington Cielle I
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Exploring the Role of a Novel Compound in Remodeling the Ovarian Tumor Microenvironment to Optimize Therapeutic Response to Metronomic Chemotherapy While Preserving Ovarian Function and Fertility
Programtype2
Studentship Programs
Orgnameinp2
University of Guelph
Cihramount2
$27,000
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Female Infertility; Fertility Preservation; Metronomic Chemotherapy; Oncofertility; Ovarian Cancer
Abstract
Ovarian cancer is the most lethal gynecological cancer, affecting 1 in 87 women worldwide. It is often diagnosed in advanced stages (III-IV) making treatment less effective. Although most cases occur in women over the age of 60, 12.1% affect those under 44, whom are still of reproductive age. Current treatments cause significant fertility damage, such as depleting the ovarian reserve and leading to infertility or premature menopause in survivors. There is a strong need for fertility preserving strategies to reduce the physical and emotion burden on women. Currently, oocyte and embryo cryopreservation exist; however, it often delays treatment that may worsen cancer outcomes. Additionally, fertility preservation itself may damage ovarian and reproductive tissue preventing successful future pregnancies. There is also a debatable concern that fertility drugs could increase ovarian cancer risk. This study combines low-dose metronomic chemotherapy with Fc3TSR, a peptide that normalizes tumor vessels to improve drug delivery. We hypothesize that Fc3TSR combined with low-dose metronomic chemotherapy will maintain ovarian functionality better than the current high-dose chemotherapy procedures. Using a mouse model, we will analyze the effects of fertility after treatment groups, including, reproductive hormone levels, ovary follicular development, oocyte fertilization capability and litter numbers. Along with analyzing fertility parameters, we will be examining the treatment effects on cancer elimination. We expect this approach to improve fertility preservation while maintaining effective cancer treatment; offering a potential treatment option for women who wish to maintain fertility.
Competitiondate
202412
Approvedterm2
1 yr 0 mth
Pinamesdelim
Lockington, Cielle I
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $27,000~ $0~